Baxter International stock (US0673431090): Gains 2.05% to $17.89

Baxter International Inc stock rose 2.05% on May 12, 2026, closing at $17.89 on the NYSE amid support at recent lows in the healthcare sector.

Baxter International Inc stock advanced 2.05% on Tuesday, May 12, 2026, climbing from an opening of $17.53 to close at $17.89 on the NYSE, ad-hoc-news.de as of May 13, 2026. Volume accumulation at the $17.53 level indicated potential buying interest, as the medical products maker navigated mixed signals in healthcare dynamics relevant to US investors.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Baxter International Inc
• Sector/industry: Medical products and healthcare
• Headquarters/country: United States
• Core markets: US, global healthcare
• Key revenue drivers: Renal care, hospital products
• Home exchange/listing venue: NYSE (BAX)
• Trading currency: USD

Baxter International: core business model

Baxter International Inc develops, manufactures and markets medical products and therapies worldwide, with a focus on hospital and renal care solutions. The company operates through segments including Medical Products and Therapies, and Kidney Care, serving acute and chronic care needs in healthcare facilities. This model positions Baxter as a key supplier in the US hospital sector, where demand for infusion systems and dialysis products remains steady.

Main revenue and product drivers for Baxter International

Key revenue drivers for Baxter International include renal care products like peritoneal dialysis solutions and continuous renal replacement therapy systems, alongside hospital products such as IV therapies and anesthesia delivery. In Q1 2026, the company reported $2.7 billion in revenue, up ~3% YoY, with international sales at $1.3 billion growing ~12% YoY, Intellectia.ai as of Apr 30, 2026. These drivers underscore Baxter's exposure to global healthcare spending, particularly in the US market.

Conclusion

Baxter International stock's 2.05% gain on May 12, 2026, highlighted support amid recent volatility, with the close at $17.89 reflecting buying interest on NYSE. The company's strong Q1 revenue growth and focus on renal and hospital products maintain its relevance for US investors tracking healthcare trends. Market conditions for medical device firms continue to evolve with sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.